A study of the sero-immunity that has protected the Swedish population against poliomyelitis for 25 years
- PMID: 2831621
- DOI: 10.3109/00365548709117192
A study of the sero-immunity that has protected the Swedish population against poliomyelitis for 25 years
Abstract
Although the population was highly susceptible to poliomyelitis on account of its low natural immunity, the general vaccination with inactivated polio vaccine eliminated poliomyelitis in Sweden within 6 years (1957-62). This status remains after 25 years, although challenges from the introduction of virus occur constantly. Over 99% of the population born in the forties and later is estimated to have been vaccinated, as well as at least 90% of those born earlier. The mean antibody levels of vaccinees against polio range from 100 (type 3) and 500 (type 1) up to 800 (type 2). Seronegative persons are seen only in a small percentage. Evaluation of the duration of immunity indicates that, after the post-vaccination fall in titre which occurs within 2-5 years after immunization, the immune levels remain fairly stable or decline very slowly. Sera from 12-year-old Swedish vaccinees neutralized the type 3 Saukett strain used for vaccine production 5 times better than a type 3 strain isolated during the Finnish outbreak 1984.
Similar articles
-
Polio immunity to killed vaccine: an 18-year follow-up.Vaccine. 1990 Oct;8(5):443-5. doi: 10.1016/0264-410x(90)90244-g. Vaccine. 1990. PMID: 2251870
-
Seroimmunity to poliomyelitis in Sweden after the use of inactivated poliovirus vaccine for 10 years.Bull World Health Organ. 1972;46(2):141-9. Bull World Health Organ. 1972. PMID: 4537478 Free PMC article.
-
Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion.J Infect Dis. 2005 Mar 15;191(6):990-9. doi: 10.1086/427810. Epub 2005 Feb 10. J Infect Dis. 2005. PMID: 15717277
-
Vaccinology of poliomyelitis.Vaccine. 1984 Mar;2(1):59-74. doi: 10.1016/s0264-410x(98)90035-4. Vaccine. 1984. PMID: 6099644 Review.
-
Eradication of poliomyelitis in the United States. II. Experience with killed poliovirus vaccine.Rev Infect Dis. 1980 Mar-Apr;2(2):243-57. doi: 10.1093/clinids/2.2.243. Rev Infect Dis. 1980. PMID: 6771867 Review.
Cited by
-
Wanted, dead or alive: new viral vaccines.Antiviral Res. 2009 Nov;84(2):119-30. doi: 10.1016/j.antiviral.2009.08.008. Epub 2009 Sep 4. Antiviral Res. 2009. PMID: 19733596 Free PMC article. Review.
-
A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines.J Infect. 2004 Oct;49(3):179-209. doi: 10.1016/j.jinf.2004.05.018. J Infect. 2004. PMID: 15337336 Free PMC article. Review.
-
[Inactivated polio vaccine].Aten Primaria. 2004 Nov 15;34(8):392-4. doi: 10.1016/s0212-6567(04)78918-0. Aten Primaria. 2004. PMID: 15546532 Free PMC article. Spanish. No abstract available.
-
Persistence of immunity following a single dose of inactivated poliovirus vaccine: a phase 4, open label, non-randomised clinical trial.Lancet Microbe. 2023 Nov;4(11):e923-e930. doi: 10.1016/S2666-5247(23)00215-X. Epub 2023 Sep 26. Lancet Microbe. 2023. PMID: 37774729 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical